symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
BBLG,0.62,0.568268,299782,1943322,0,0.503-16.8,0.019,Bone Biologics Corporation,USD,0001419554,US0980703039,098070303,NASDAQ Capital Market,NASDAQ,Medical Devices,https://www.bonebiologics.com,"Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.",Mr. Jeffrey  Frelick,Healthcare,US,2,781 552 4452,2 Burlington Woods Drive,Burlington,MA,01803,,0,https://financialmodelingprep.com/image-stock/BBLG.png,2021-10-13,False,False,True,False,False
